Tesamorelin and ipamorelin both push the pituitary gland to release growth hormone, but they do it through two different signals and sit in very different places legally. When people compare tesamorelin vs ipamorelin, the most important difference is this: tesamorelin is an FDA-approved prescription drug with large human trials behind it, while ipamorelin has never been approved and has far less human data.
This guide explains how each compound works, what published studies actually found, and where the evidence stops.
Key takeaways
- Tesamorelin copies growth hormone-releasing hormone (GHRH), the body’s own “release growth hormone” signal. The FDA approved it in November 2010 to reduce excess belly fat in people with HIV-related lipodystrophy.
- Ipamorelin works on a different receptor, the one used by the hormone ghrelin. Most of its research comes from animal and early human studies.
- The only mid-stage human trial of ipamorelin, in patients recovering from bowel surgery, did not show a significant benefit over placebo.
- Both compounds are banned in sport at all times under World Anti-Doping Agency (WADA) rules.
Tesamorelin vs Ipamorelin at a Glance
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| What it is | A synthetic chain of 44 amino acids, built as a copy of GHRH | A synthetic chain of 5 amino acids, a pentapeptide |
| Signal it copies | GHRH, the brain’s growth hormone release signal | Ghrelin, acting on the ghrelin receptor |
| FDA status | Approved in 2010 as Egrifta, for excess belly fat in HIV-related lipodystrophy | Not approved. On the FDA’s Category 2 list of compounding substances that may pose significant safety risks |
| Largest human studies | Two phase 3 trials with 412 and 404 patients | One phase 2 trial with 117 surgical patients |
| Half-life | 26 to 38 minutes | About 2 hours |
| WADA status | Prohibited at all times | Prohibited at all times |
Half-life is the time it takes for half of a compound to clear from the blood. The two half-life figures come from separate studies in different groups of people, so they show a general difference rather than a head-to-head result. Sources for this table: [1], [4], [5], [6], [7], [8].
What Is Tesamorelin?
Tesamorelin is a lab-made peptide, meaning a short chain of amino acids (the building blocks of proteins). It is 44 amino acids long and is designed as an analog, or close copy, of growth hormone-releasing factor, with a small chemical group added to one end [1].
The FDA approved it on November 10, 2010, under the brand name Egrifta [2] [3]. Its approved use is narrow: reducing excess abdominal fat in people with HIV who have lipodystrophy, a condition in which body fat builds up or is lost in unusual places. The label also states that it is not indicated for weight loss [1].
How Does Tesamorelin Work?
The body normally controls growth hormone with a chemical message called GHRH, which tells the pituitary gland to release growth hormone.
Tesamorelin is built as a copy of that message [1]. A simple way to picture it: if growth hormone release is a locked door, GHRH is the key the body already uses, and tesamorelin is a copy of that same key.
One measurable sign of this effect is a rise in IGF-1 (insulin-like growth factor 1), a hormone that goes up when growth hormone goes up. In the phase 3 trials, 47.4% of people taking tesamorelin had IGF-1 levels more than 2 standard deviations above average at 26 weeks, which means well above the usual range [1].
What Is Ipamorelin?
Ipamorelin is a much smaller lab-made peptide, only 5 amino acids long. A research team described it in 1998 in the European Journal of Endocrinology, calling it “the first selective growth hormone secretagogue” [4]. A growth hormone secretagogue is any compound that causes the body to release more growth hormone.
It was created by shortening an older compound called GHRP-1, and it belongs to the same family as peptides such as GHRP-2 and GHRP-6 [4].
What Does Ipamorelin Do in the Body?
Ipamorelin acts on the ghrelin receptor, which is why researchers describe it as a ghrelin mimetic, or ghrelin copy [6]. Activating this receptor also leads the pituitary gland to release growth hormone, but through a separate route from GHRH [4].
The word “selective” is the main reason ipamorelin drew interest. In the 1998 study, which used rat pituitary cells, live rats and pigs, researchers reported that:
- Ipamorelin released growth hormone about as strongly as GHRP-6 [4].
- Unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol (stress hormones) beyond levels seen with GHRH, even at doses 200 times higher than needed for growth hormone release [4].
- It had no effect on FSH, LH, prolactin or TSH, four other hormones made by the pituitary [4].
These were animal results, so they do not show how ipamorelin behaves in people. A 1999 study in healthy male volunteers found that growth hormone peaked about 40 minutes (0.67 hours) after an infusion of ipamorelin [5].
Do Tesamorelin and Ipamorelin Work the Same Way?
No. The end result is the same, growth hormone released from the pituitary gland, but the starting signal is different. That is the core difference between ipamorelin and tesamorelin.
- Tesamorelin sends a GHRH-type signal.
- Ipamorelin sends a ghrelin-type signal through a different receptor.
Think of two light switches wired to the same lamp. Either switch can turn the light on, but each has its own wiring. This is also why anti-doping rules list them in two separate groups: tesamorelin with the GHRH analogues, and ipamorelin with the growth hormone secretagogues [8] [9].
[embed: node/37820c01-5314]
Both compounds end at the same gland and the same hormone. What differs is the receptor each one uses to get there.
What Does the Research Say?
The evidence gap between the two compounds is large. Tesamorelin has two placebo-controlled phase 3 trials with 816 patients in total [1]. Ipamorelin has animal work, a small study in healthy volunteers and one phase 2 trial that missed its main goal [4] [5] [6].
| Study | Study type | Who or what was studied | Key finding |
|---|---|---|---|
| Raun et al., 1998 [4] | Cell and animal study | Rat pituitary cells, rats and pigs | Ipamorelin released growth hormone about as strongly as GHRP-6 without raising ACTH or cortisol |
| Gobburu et al., 1999 [5] | Early human study | Healthy men, 8 per dose level across 5 dose levels | Half-life of about 2 hours; one growth hormone peak about 40 minutes after infusion |
| Tesamorelin phase 3, Study 1 [1] | Randomized, placebo-controlled human trial | 412 people with HIV-related lipodystrophy, 26 weeks | Visceral fat fell 18% with tesamorelin and rose 2% with placebo |
| Tesamorelin phase 3, Study 2 [1] | Randomized, placebo-controlled human trial | 404 people with HIV-related lipodystrophy, 26 weeks | Visceral fat fell 14% with tesamorelin and 2% with placebo |
| Beck et al., 2014 [6] | Randomized, placebo-controlled phase 2 human trial | 117 adults after bowel surgery | Time to first tolerated meal was 25.3 hours with ipamorelin vs 32.6 hours with placebo; the difference was not statistically significant (p = 0.15) |
Two terms in this table are worth explaining:
- Visceral fat is the deep belly fat that sits around the organs, as opposed to the fat just under the skin.
- Not statistically significant means the gap between groups was small enough that it could have happened by chance, so the trial could not show a real effect.
Which One Has More Evidence for Fat Loss?
Tesamorelin, by a wide margin, but only for one specific kind of fat in one patient group. In both phase 3 trials, people with HIV-related lipodystrophy lost visceral fat compared with placebo over 26 weeks. Even so, the FDA label says the drug is not indicated for weight loss and describes its effect on body weight as neutral [1]. In other words, it reduced deep belly fat without lowering the number on the scale.
For ipamorelin, there is no published human trial that measured fat loss. Its human studies looked at how long it stays in the blood and at recovery after bowel surgery [5] [6].
Does Tesamorelin Help Build Muscle?
The evidence here is limited. In the phase 3 trials, lean body mass (everything in the body except fat, including muscle, organs and water) rose by an average of 1.3 kg in Study 1 and 1.2 kg in Study 2. In the placebo groups it fell slightly, by 0.2 kg and 0.03 kg [1].
Three points keep this result in proportion:
- Lean body mass is not the same as muscle, so the trials do not show how much of the gain was muscle tissue.
- All participants had HIV-related lipodystrophy, so the results may not apply to healthy adults.
- Building muscle is not an approved use, and no published trial has tested tesamorelin for muscle growth in healthy people.
Why Are Tesamorelin and Ipamorelin Studied Together?
Interest in a tesamorelin ipamorelin blend comes from the two-switch idea above. Because each compound uses a different signal to reach the same gland, the theory is that two signals may add up to more than one.
That theory has not been tested in the way the individual compounds have. No published human trial has tested tesamorelin and ipamorelin together. Any claim about what the combination does should therefore be treated as unproven. The same logic sits behind pairing CJC-1295 with ipamorelin, another GHRH-type compound matched with a ghrelin-type one.
How Do They Compare With Sermorelin and CJC-1295?
Sermorelin and CJC-1295 sit in the same group as tesamorelin. Anti-doping rules list all three as GHRH analogues, while ipamorelin is listed separately as a growth hormone secretagogue [8].
| Compound | Signal type | Same group as |
|---|---|---|
| Tesamorelin | GHRH analogue | Sermorelin, CJC-1295 |
| Sermorelin | GHRH analogue | Tesamorelin, CJC-1295 |
| CJC-1295 | GHRH analogue | Tesamorelin, sermorelin |
| Ipamorelin | Growth hormone secretagogue | GHRP-2, GHRP-6 |
So a comparison of tesamorelin vs sermorelin vs ipamorelin is really two GHRH-type compounds against one ghrelin-type compound.
Side Effects Reported in Studies
The safety data for these two compounds is very uneven, so the sections below are not a like-for-like comparison.
Tesamorelin
The FDA label lists these as the most common side effects, seen in at least 5% of trial participants and more often than with placebo [1]:
| Side effect | Plain meaning | Rate |
|---|---|---|
| Arthralgia | Joint pain | 13.3% |
| Injection site erythema | Redness where the shot was given | 8.5% |
| Injection site pruritus | Itching where the shot was given | 7.6% |
| Pain in extremity | Pain in the arms or legs | 6.1% |
| Peripheral edema | Swelling, often in the hands or feet | 6.1% |
| Myalgia | Muscle pain | 5.5% |
The label also warns about:
- Higher blood sugar. HbA1c, a measure of average blood sugar, reached 6.5% or more in 4.5% of people on tesamorelin vs 1.3% on placebo [1].
- Fluid retention, including swelling and carpal tunnel syndrome, thought to be linked to the rise in growth hormone [1].
- Allergic-type reactions such as itching, redness and hives, reported in 3.6% of patients [1].
Ipamorelin
Human safety data for ipamorelin is limited. In the 2014 bowel surgery trial, side effects of any kind were reported in 87.5% of the ipamorelin group and 94.8% of the placebo group, with no meaningful difference between them [6]. Those high rates reflect recovery from major surgery, not the drug alone.
The FDA has raised separate concerns. It notes that ipamorelin may cause unwanted immune reactions, may contain peptide-related impurities, and that published reports describe serious adverse events, including death, when it was given intravenously [7].
Who Was Excluded From Tesamorelin Use?
The FDA label says tesamorelin should not be used in people with [1]:
- Damage to or removal of the pituitary gland, a pituitary tumor, or head radiation or injury
- Active cancer
- A known allergy to tesamorelin or mannitol (an ingredient in the product)
- Pregnancy
Is Tesamorelin FDA Approved? Legal Status of Both
| Question | Tesamorelin | Ipamorelin |
|---|---|---|
| FDA approved? | Yes, since November 2010, for excess abdominal fat in HIV-related lipodystrophy only | No. It has only been tested as an investigational drug |
| On the FDA Category 2 compounding list? | No | Yes, added September 29, 2023 |
| Banned in sport? | Yes, at all times | Yes, at all times |
The FDA’s Category 2 list covers bulk substances that “may present significant safety risks” when used in compounding, the process pharmacies use to prepare custom medicines [7]. For athletes, both compounds fall under class S2 of the anti-doping list, which is prohibited both in and out of competition [8] [9].
Frequently Asked Questions
What is the difference between tesamorelin and ipamorelin?
Tesamorelin copies GHRH, the body’s own signal for growth hormone release, and is an FDA-approved drug for excess belly fat in HIV-related lipodystrophy. Ipamorelin acts on the ghrelin receptor instead and has never been approved. Both lead to growth hormone release, but through different routes and with very different amounts of human evidence.
Which is stronger, tesamorelin or ipamorelin?
No study has compared them head to head, so there is no fair answer on strength. What can be compared is evidence. Tesamorelin has two phase 3 trials with 816 patients. Ipamorelin’s largest human trial had 117 patients and did not meet its main goal. On evidence, tesamorelin is far ahead.
Is tesamorelin FDA approved?
Yes. The FDA approved tesamorelin, sold as Egrifta, in November 2010. The approval covers one use only: reducing excess abdominal fat in people with HIV who have lipodystrophy. The label states that it is not indicated for weight loss, and that long-term heart safety has not been studied [1].
Is ipamorelin FDA approved?
No. Ipamorelin has only been tested as an investigational drug, and its phase 2 trial in bowel surgery patients did not show a significant benefit. In 2023, the FDA placed it on its Category 2 list of compounding substances that may present significant safety risks.
Can tesamorelin and ipamorelin be used together in research?
They are often discussed as a pair because they use two different signals to reach the same gland. However, we found no published human trial testing the two together. That means there is no clinical evidence on how the combination works or how safe it is, and claims about blends remain unproven.
Is tesamorelin a steroid?
No. Tesamorelin is a peptide, a chain of 44 amino acids built to copy a natural signalling hormone [1]. Anabolic steroids are synthetic versions of testosterone, the main male sex hormone [10]. The two belong to different chemical classes and act on the body in different ways.
Does ipamorelin raise cortisol?
In the 1998 animal and cell study that first described it, ipamorelin did not raise ACTH or cortisol beyond levels seen with GHRH, even at very high doses. Two related compounds, GHRP-2 and GHRP-6, did raise them. These were animal results, and human data on this question is limited.
Where Do Researchers Source Tesamorelin and Ipamorelin?
For laboratory studies, researchers source peptides such as tesamorelin and ipamorelin from specialized suppliers that provide compounds strictly for research use. Because the quality of a compound can affect study results, research teams usually check a supplier for:
- Batch purity testing, which shows how much of the vial is the intended peptide and how much is something else
- A certificate of analysis (COA), a lab report that confirms the identity and purity of each batch
- Clear research-use-only labeling on every product
Researchers often source peptides from trusted platforms such as PeptidePro, which supplies research compounds for laboratory and scientific study. All such compounds are intended for research purposes only and not for human consumption.
Disclaimer
This article is provided for educational and informational purposes only and does not constitute medical advice. The compounds discussed are research compounds and are not intended for human consumption. Anyone considering the use of any peptide should first consult a qualified, licensed healthcare professional, who can assess their individual circumstances and advise on what is most appropriate for them.
References
- U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) prescribing information. Revised 2012.
- HIV Treatment Bulletin (i-Base). FDA approves tesamorelin for reduction of central fat accumulation. 2010.
- HealthDay. Egrifta approved for HIV-related fat deposits. November 2010.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Gobburu JVS, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416.
- Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29:1527-1534.
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Updated April 22, 2026.
- World Anti-Doping Agency. The 2020 Prohibited List, International Standard. Section S2.
- Voluntary Anti-Doping Association. VADA Prohibited List 2026, which tracks the WADA 2026 Prohibited List. Section S2.2.4.
- MedlinePlus, U.S. National Library of Medicine. Anabolic steroids.